Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

ensifentrine (Ohtuvayre)

Notes:

• Quantity Limits: Yes

<u>Initiation (new start) criteria</u>: Non-formulary **ensifentrine (Ohtuvayre)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a pulmonologist
- Patient has a diagnosis of chronic obstructive pulmonary disorder (COPD)
- Patient does not smoke or vape (tobacco, cannabis) based on prescriber determination.
- Patient has a history of use of and will continue on, or has a contraindication or failure to, the following therapies and combinations:
 - i. LABA (long-acting beta-2-agonist) or LAMA (long-acting antimuscarinic), with or without an ICS (inhaled corticosteroid)
 - ii. LABA + LAMA combination, with or without an ICS

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary ensifentrine
(Ohtuvayre) will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a pulmonologist
- Patient has a diagnosis of chronic obstructive pulmonary disorder (COPD)
- Patient reports they do not smoke or vape (tobacco, cannabis).
- Patient is using ensifentrine (Ohtuvayre) in combination with, or has a contraindication or failure to, the following therapies and combinations:
 - i. LABA (long-acting beta-2-agonist) or LAMA (long-acting antimuscarinic), with or without an ICS (inhaled corticosteroid)
 - ii. LABA + LAMA combination, with or without an ICS

kp.org

Revised: 04/10/25 Effective: 06/19/25 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

